A simulation study comparing the power of nine tests of the treatment effect in randomized controlled trials with a time-to-event outcome
The logrank test is routinely applied to design and analyse randomized controlled trials (RCTs) with time-to-event outcomes. Sample size and power calculations assume the treatment effect follows proportional hazards (PH). If the PH assumption is false, power is reduced and interpretation of the haz...
Gespeichert in:
Veröffentlicht in: | Current controlled trials in cardiovascular medicine 2020-04, Vol.21 (1), p.315-315, Article 315 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 315 |
---|---|
container_issue | 1 |
container_start_page | 315 |
container_title | Current controlled trials in cardiovascular medicine |
container_volume | 21 |
creator | Royston, Patrick B Parmar, Mahesh K |
description | The logrank test is routinely applied to design and analyse randomized controlled trials (RCTs) with time-to-event outcomes. Sample size and power calculations assume the treatment effect follows proportional hazards (PH). If the PH assumption is false, power is reduced and interpretation of the hazard ratio (HR) as the estimated treatment effect is compromised. Using statistical simulation, we investigated the type 1 error and power of the logrank (LR)test and eight alternatives. We aimed to identify test(s) that improve power with three types of non-proportional hazards (non-PH): early, late or near-PH treatment effects.
We investigated weighted logrank tests (early, LRE; late, LRL), the supremum logrank test (SupLR) and composite tests (joint, J; combined, C; weighted combined, WC; versatile and modified versatile weighted logrank, VWLR, VWLR2) with two or more components. Weighted logrank tests are intended to be sensitive to particular non-PH patterns. Composite tests attempt to improve power across a wider range of non-PH patterns. Using extensive simulations based on real trials, we studied test size and power under PH and under simple departures from PH comprising pointwise constant HRs with a single change point at various follow-up times. We systematically investigated the influence of high or low control-arm event rates on power.
With no preconceived type of treatment effect, the preferred test is VWLR2. Expecting an early effect, tests with acceptable power are SupLR, C, VWLR2, J, LRE and WC. Expecting a late effect, acceptable tests are LRL, VWLR, VWLR2, WC and J. Under near-PH, acceptable tests are LR, LRE, VWLR, C, VWLR2 and SupLR. Type 1 error was well controlled for all tests, showing only minor deviations from the nominal 5%. The location of the HR change point relative to the cumulative proportion of control-arm events considerably affected power.
Assuming ignorance of the likely treatment effect, the best choice is VWLR2. Several non-standard tests performed well when the correct type of treatment effect was assumed. A low control-arm event rate reduced the power of weighted logrank tests targeting early effects. Test size was generally well controlled. Further investigation of test characteristics with different types of non-proportional hazards of the treatment effect is warranted. |
doi_str_mv | 10.1186/s13063-020-4153-2 |
format | Article |
fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_gale_infotracacademiconefile_A619649051</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A619649051</galeid><doaj_id>oai_doaj_org_article_4a91492be1ee42f48b9bbd1a566032d4</doaj_id><sourcerecordid>A619649051</sourcerecordid><originalsourceid>FETCH-LOGICAL-c560t-9b8414df91e48e7bf2cc94d709d602d71c9287f3c2a49fbb7fb981f52f3cbc53</originalsourceid><addsrcrecordid>eNptUstuFDEQHCEQCQsfwAVZ4pLLBL_m4QvSKgoQKRKX3C2P3d71asZebE-i5A_4azxsCFmEfLDdXVXtbldVvSf4nJC-_ZQIwy2rMcU1Jw2r6YvqlHS8qVtKmpfPzifVm5R2GHMmGH9dnTBKG9pTfFr9XKPkpnlU2QWPUp7NPdJh2qvo_AblLaB9uIOIgkXeeUAZUk7LbUnlCCpP4DMCa0Fn5DyKypswuQcwRcfnGMaxHHN0akzozuUtUii7CeocarhduGHOpSK8rV7ZgoF3j_uquvlyeXPxrb7-_vXqYn1d66bFuRZDzwk3VhDgPXSDpVoLbjosTIup6YgWtO8s01RxYYehs4PoiW1oCQ26Yavq6iBrgtrJfXSTivcyKCd_B0LcSBWz0yNIrgThgg5AADi1vB_EMBiimrbFjBpetD4ftPbzMIHRpZuoxiPR44x3W7kJt7IjjPaiLwJnjwIx_JjLaOXkkoZxVB7CnCRlfUeblvYL9OM_0F2Yoy-TkrRjmHHCWPsXtVGlAedtKHX1IirXLREtF7ghBXX-H1RZBiZXfg2sK_EjAjkQdAwpRbBPPRIsFyvKgxVlsaJcrFhevqo-PB_OE-OP99gvfKDa_Q</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2730341336</pqid></control><display><type>article</type><title>A simulation study comparing the power of nine tests of the treatment effect in randomized controlled trials with a time-to-event outcome</title><source>SpringerOpen</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>PubMed Central</source><source>SpringerLink Journals - AutoHoldings</source><creator>Royston, Patrick ; B Parmar, Mahesh K</creator><creatorcontrib>Royston, Patrick ; B Parmar, Mahesh K</creatorcontrib><description>The logrank test is routinely applied to design and analyse randomized controlled trials (RCTs) with time-to-event outcomes. Sample size and power calculations assume the treatment effect follows proportional hazards (PH). If the PH assumption is false, power is reduced and interpretation of the hazard ratio (HR) as the estimated treatment effect is compromised. Using statistical simulation, we investigated the type 1 error and power of the logrank (LR)test and eight alternatives. We aimed to identify test(s) that improve power with three types of non-proportional hazards (non-PH): early, late or near-PH treatment effects.
We investigated weighted logrank tests (early, LRE; late, LRL), the supremum logrank test (SupLR) and composite tests (joint, J; combined, C; weighted combined, WC; versatile and modified versatile weighted logrank, VWLR, VWLR2) with two or more components. Weighted logrank tests are intended to be sensitive to particular non-PH patterns. Composite tests attempt to improve power across a wider range of non-PH patterns. Using extensive simulations based on real trials, we studied test size and power under PH and under simple departures from PH comprising pointwise constant HRs with a single change point at various follow-up times. We systematically investigated the influence of high or low control-arm event rates on power.
With no preconceived type of treatment effect, the preferred test is VWLR2. Expecting an early effect, tests with acceptable power are SupLR, C, VWLR2, J, LRE and WC. Expecting a late effect, acceptable tests are LRL, VWLR, VWLR2, WC and J. Under near-PH, acceptable tests are LR, LRE, VWLR, C, VWLR2 and SupLR. Type 1 error was well controlled for all tests, showing only minor deviations from the nominal 5%. The location of the HR change point relative to the cumulative proportion of control-arm events considerably affected power.
Assuming ignorance of the likely treatment effect, the best choice is VWLR2. Several non-standard tests performed well when the correct type of treatment effect was assumed. A low control-arm event rate reduced the power of weighted logrank tests targeting early effects. Test size was generally well controlled. Further investigation of test characteristics with different types of non-proportional hazards of the treatment effect is warranted.</description><identifier>ISSN: 1745-6215</identifier><identifier>EISSN: 1745-6215</identifier><identifier>DOI: 10.1186/s13063-020-4153-2</identifier><identifier>PMID: 32252820</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Clinical trials ; Computer Simulation ; Hazard ratio ; Humans ; Hypotheses ; Logrank test ; Medical research ; Methodology ; Non-proportional hazards ; Power ; Power (Philosophy) ; Proportional Hazards Models ; Randomized controlled trials ; Randomized Controlled Trials as Topic ; Research Design ; Sample Size ; Simulation ; Time ; Time-to-event outcome ; Versatile test</subject><ispartof>Current controlled trials in cardiovascular medicine, 2020-04, Vol.21 (1), p.315-315, Article 315</ispartof><rights>COPYRIGHT 2020 BioMed Central Ltd.</rights><rights>The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c560t-9b8414df91e48e7bf2cc94d709d602d71c9287f3c2a49fbb7fb981f52f3cbc53</citedby><cites>FETCH-LOGICAL-c560t-9b8414df91e48e7bf2cc94d709d602d71c9287f3c2a49fbb7fb981f52f3cbc53</cites><orcidid>0000-0001-6386-4410</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132898/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132898/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2102,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32252820$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Royston, Patrick</creatorcontrib><creatorcontrib>B Parmar, Mahesh K</creatorcontrib><title>A simulation study comparing the power of nine tests of the treatment effect in randomized controlled trials with a time-to-event outcome</title><title>Current controlled trials in cardiovascular medicine</title><addtitle>Trials</addtitle><description>The logrank test is routinely applied to design and analyse randomized controlled trials (RCTs) with time-to-event outcomes. Sample size and power calculations assume the treatment effect follows proportional hazards (PH). If the PH assumption is false, power is reduced and interpretation of the hazard ratio (HR) as the estimated treatment effect is compromised. Using statistical simulation, we investigated the type 1 error and power of the logrank (LR)test and eight alternatives. We aimed to identify test(s) that improve power with three types of non-proportional hazards (non-PH): early, late or near-PH treatment effects.
We investigated weighted logrank tests (early, LRE; late, LRL), the supremum logrank test (SupLR) and composite tests (joint, J; combined, C; weighted combined, WC; versatile and modified versatile weighted logrank, VWLR, VWLR2) with two or more components. Weighted logrank tests are intended to be sensitive to particular non-PH patterns. Composite tests attempt to improve power across a wider range of non-PH patterns. Using extensive simulations based on real trials, we studied test size and power under PH and under simple departures from PH comprising pointwise constant HRs with a single change point at various follow-up times. We systematically investigated the influence of high or low control-arm event rates on power.
With no preconceived type of treatment effect, the preferred test is VWLR2. Expecting an early effect, tests with acceptable power are SupLR, C, VWLR2, J, LRE and WC. Expecting a late effect, acceptable tests are LRL, VWLR, VWLR2, WC and J. Under near-PH, acceptable tests are LR, LRE, VWLR, C, VWLR2 and SupLR. Type 1 error was well controlled for all tests, showing only minor deviations from the nominal 5%. The location of the HR change point relative to the cumulative proportion of control-arm events considerably affected power.
Assuming ignorance of the likely treatment effect, the best choice is VWLR2. Several non-standard tests performed well when the correct type of treatment effect was assumed. A low control-arm event rate reduced the power of weighted logrank tests targeting early effects. Test size was generally well controlled. Further investigation of test characteristics with different types of non-proportional hazards of the treatment effect is warranted.</description><subject>Clinical trials</subject><subject>Computer Simulation</subject><subject>Hazard ratio</subject><subject>Humans</subject><subject>Hypotheses</subject><subject>Logrank test</subject><subject>Medical research</subject><subject>Methodology</subject><subject>Non-proportional hazards</subject><subject>Power</subject><subject>Power (Philosophy)</subject><subject>Proportional Hazards Models</subject><subject>Randomized controlled trials</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Research Design</subject><subject>Sample Size</subject><subject>Simulation</subject><subject>Time</subject><subject>Time-to-event outcome</subject><subject>Versatile test</subject><issn>1745-6215</issn><issn>1745-6215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>DOA</sourceid><recordid>eNptUstuFDEQHCEQCQsfwAVZ4pLLBL_m4QvSKgoQKRKX3C2P3d71asZebE-i5A_4azxsCFmEfLDdXVXtbldVvSf4nJC-_ZQIwy2rMcU1Jw2r6YvqlHS8qVtKmpfPzifVm5R2GHMmGH9dnTBKG9pTfFr9XKPkpnlU2QWPUp7NPdJh2qvo_AblLaB9uIOIgkXeeUAZUk7LbUnlCCpP4DMCa0Fn5DyKypswuQcwRcfnGMaxHHN0akzozuUtUii7CeocarhduGHOpSK8rV7ZgoF3j_uquvlyeXPxrb7-_vXqYn1d66bFuRZDzwk3VhDgPXSDpVoLbjosTIup6YgWtO8s01RxYYehs4PoiW1oCQ26Yavq6iBrgtrJfXSTivcyKCd_B0LcSBWz0yNIrgThgg5AADi1vB_EMBiimrbFjBpetD4ftPbzMIHRpZuoxiPR44x3W7kJt7IjjPaiLwJnjwIx_JjLaOXkkoZxVB7CnCRlfUeblvYL9OM_0F2Yoy-TkrRjmHHCWPsXtVGlAedtKHX1IirXLREtF7ghBXX-H1RZBiZXfg2sK_EjAjkQdAwpRbBPPRIsFyvKgxVlsaJcrFhevqo-PB_OE-OP99gvfKDa_Q</recordid><startdate>20200406</startdate><enddate>20200406</enddate><creator>Royston, Patrick</creator><creator>B Parmar, Mahesh K</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-6386-4410</orcidid></search><sort><creationdate>20200406</creationdate><title>A simulation study comparing the power of nine tests of the treatment effect in randomized controlled trials with a time-to-event outcome</title><author>Royston, Patrick ; B Parmar, Mahesh K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c560t-9b8414df91e48e7bf2cc94d709d602d71c9287f3c2a49fbb7fb981f52f3cbc53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Clinical trials</topic><topic>Computer Simulation</topic><topic>Hazard ratio</topic><topic>Humans</topic><topic>Hypotheses</topic><topic>Logrank test</topic><topic>Medical research</topic><topic>Methodology</topic><topic>Non-proportional hazards</topic><topic>Power</topic><topic>Power (Philosophy)</topic><topic>Proportional Hazards Models</topic><topic>Randomized controlled trials</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Research Design</topic><topic>Sample Size</topic><topic>Simulation</topic><topic>Time</topic><topic>Time-to-event outcome</topic><topic>Versatile test</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Royston, Patrick</creatorcontrib><creatorcontrib>B Parmar, Mahesh K</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing & Allied Health Database</collection><collection>Health & Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Current controlled trials in cardiovascular medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Royston, Patrick</au><au>B Parmar, Mahesh K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A simulation study comparing the power of nine tests of the treatment effect in randomized controlled trials with a time-to-event outcome</atitle><jtitle>Current controlled trials in cardiovascular medicine</jtitle><addtitle>Trials</addtitle><date>2020-04-06</date><risdate>2020</risdate><volume>21</volume><issue>1</issue><spage>315</spage><epage>315</epage><pages>315-315</pages><artnum>315</artnum><issn>1745-6215</issn><eissn>1745-6215</eissn><abstract>The logrank test is routinely applied to design and analyse randomized controlled trials (RCTs) with time-to-event outcomes. Sample size and power calculations assume the treatment effect follows proportional hazards (PH). If the PH assumption is false, power is reduced and interpretation of the hazard ratio (HR) as the estimated treatment effect is compromised. Using statistical simulation, we investigated the type 1 error and power of the logrank (LR)test and eight alternatives. We aimed to identify test(s) that improve power with three types of non-proportional hazards (non-PH): early, late or near-PH treatment effects.
We investigated weighted logrank tests (early, LRE; late, LRL), the supremum logrank test (SupLR) and composite tests (joint, J; combined, C; weighted combined, WC; versatile and modified versatile weighted logrank, VWLR, VWLR2) with two or more components. Weighted logrank tests are intended to be sensitive to particular non-PH patterns. Composite tests attempt to improve power across a wider range of non-PH patterns. Using extensive simulations based on real trials, we studied test size and power under PH and under simple departures from PH comprising pointwise constant HRs with a single change point at various follow-up times. We systematically investigated the influence of high or low control-arm event rates on power.
With no preconceived type of treatment effect, the preferred test is VWLR2. Expecting an early effect, tests with acceptable power are SupLR, C, VWLR2, J, LRE and WC. Expecting a late effect, acceptable tests are LRL, VWLR, VWLR2, WC and J. Under near-PH, acceptable tests are LR, LRE, VWLR, C, VWLR2 and SupLR. Type 1 error was well controlled for all tests, showing only minor deviations from the nominal 5%. The location of the HR change point relative to the cumulative proportion of control-arm events considerably affected power.
Assuming ignorance of the likely treatment effect, the best choice is VWLR2. Several non-standard tests performed well when the correct type of treatment effect was assumed. A low control-arm event rate reduced the power of weighted logrank tests targeting early effects. Test size was generally well controlled. Further investigation of test characteristics with different types of non-proportional hazards of the treatment effect is warranted.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>32252820</pmid><doi>10.1186/s13063-020-4153-2</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-6386-4410</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1745-6215 |
ispartof | Current controlled trials in cardiovascular medicine, 2020-04, Vol.21 (1), p.315-315, Article 315 |
issn | 1745-6215 1745-6215 |
language | eng |
recordid | cdi_gale_infotracacademiconefile_A619649051 |
source | SpringerOpen; MEDLINE; DOAJ Directory of Open Access Journals; PubMed Central Open Access; PubMed Central; SpringerLink Journals - AutoHoldings |
subjects | Clinical trials Computer Simulation Hazard ratio Humans Hypotheses Logrank test Medical research Methodology Non-proportional hazards Power Power (Philosophy) Proportional Hazards Models Randomized controlled trials Randomized Controlled Trials as Topic Research Design Sample Size Simulation Time Time-to-event outcome Versatile test |
title | A simulation study comparing the power of nine tests of the treatment effect in randomized controlled trials with a time-to-event outcome |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T18%3A42%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20simulation%20study%20comparing%20the%20power%20of%20nine%20tests%20of%20the%20treatment%20effect%20in%20randomized%20controlled%20trials%20with%20a%20time-to-event%20outcome&rft.jtitle=Current%20controlled%20trials%20in%20cardiovascular%20medicine&rft.au=Royston,%20Patrick&rft.date=2020-04-06&rft.volume=21&rft.issue=1&rft.spage=315&rft.epage=315&rft.pages=315-315&rft.artnum=315&rft.issn=1745-6215&rft.eissn=1745-6215&rft_id=info:doi/10.1186/s13063-020-4153-2&rft_dat=%3Cgale_doaj_%3EA619649051%3C/gale_doaj_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2730341336&rft_id=info:pmid/32252820&rft_galeid=A619649051&rft_doaj_id=oai_doaj_org_article_4a91492be1ee42f48b9bbd1a566032d4&rfr_iscdi=true |